Sarcopenic Obesity: When Muscle Loss Hides Under Weight Gain

What is sarcopenic obesity?

Sarcopenic obesity is excess body fat and low muscle mass or function occurring together — and since 2022 it has had a formal European definition of its own.

The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) published a joint consensus statement that puts it plainly: "Sarcopenic obesity is defined as the co-existence of obesity and sarcopenia." Donini et al., Obesity Facts, 2022

That statement exists because the condition kept falling between two stools. The revised European sarcopenia consensus, EWGSOP2, describes sarcopenic obesity as "a condition of reduced lean body mass in the context of excess adiposity", calls it "a distinct condition", and then says it is "therefore outside of the scope of this article". Cruz-Jentoft et al., Age and Ageing, 2019 The sarcopenia guidance pointed at it; the obesity guidance did not own it. The 2022 consensus was written to close that gap.

For the underlying condition, see what sarcopenia is — and why it is defined by strength, not size.

Why does muscle loss hide under a stable or rising weight?

Because weight is one number covering fat, muscle, bone and water — so what it is made of can change while the number barely moves.

A UK cohort study of older men put the mechanism in a sentence: "although body weight and body mass index (BMI) may remain relatively unchanged, typically visceral fat increases and muscle mass decreases". Atkins et al., Journal of the American Geriatrics Society, 2014

The ESPEN and EASO panel took that problem seriously enough to build it into the definition. Rather than asking whether absolute muscle mass has dropped, the consensus judges muscle mass adjusted to body weight — appendicular lean mass over weight on DXA, or skeletal muscle mass over weight on bioelectrical impedance. Its stated reasoning is that "a relative reduction of muscle mass in the presence of high total body mass and FM may have relevant clinical and functional impact even in the absence of absolute muscle mass reduction". Donini et al., Obesity Facts, 2022

That is the whole condition in one line: you need not lose muscle in absolute terms to be carrying too little for the body you now have.

How is sarcopenic obesity diagnosed?

In three stages — screen, diagnose, stage — with muscle function tested before any scan. ESPEN's own summary of its consensus sets out the sequence, and both halves of each stage must be present before you proceed. ESPEN fact sheet, Sarcopenic Obesity

Stage	What happens	What must be found
1. Screening	Raised BMI or waist circumference plus surrogate indicators of sarcopenia (symptoms, risk factors, or a questionnaire such as SARC-F)	Both, to proceed
2. Diagnosis	Altered muscle function first (grip strength, chair-stand test), then altered body composition (high fat percentage, low weight-adjusted muscle mass)	Both, to confirm
3. Staging	Stage I or Stage II, according to complications	Presence or absence of complications

In the consensus's wording, "the group supports the assessment of skeletal muscle strength" — hand-grip strength, knee extensor strength, or a chair-stand test. Only then does imaging enter: "the group supports its assessment by dual-energy X-ray absorptiometry (DXA), or bioelectrical impedance analysis (BIA) as an alternative second choice", with CT used where someone is having one anyway. Staging then splits confirmed cases in two by whether any complication attributable to the altered body composition and muscle function is present. Donini et al., Obesity Facts, 2022

Two things follow. What starts the process is a strength test, not a scan — which is why grip strength keeps surfacing as a cheap, informative number. What confirms it is a DEXA body composition scan, the method the consensus names first.

Who is at risk of sarcopenic obesity?

Age plus excess weight is the headline combination — but it is not confined to older people.

The consensus proposes that "all people with obesity and overweight above the age of 70 should be considered at risk of SO, due to the additional risk of developing age-related sarcopenia", adding chronic diseases that drive muscle loss as further risk factors. It also declines to file the condition purely as a geriatric one: "Sarcopenic obesity can, therefore, also be observed in middle-aged and younger individuals with obesity", often alongside acute or chronic disease, rapid weight change, or weight cycling after weight-loss treatment. Donini et al., Obesity Facts, 2022

How common it is depends heavily on the criteria applied: a later clinical overview states that "The prevalence of sarcopenic obesity in older adults varies substantially, depending on which diagnostic criteria are applied". Prado et al., Nature Reviews Endocrinology, 2024 Treat any single headline percentage with suspicion.

Does BMI pick up sarcopenic obesity?

No. In the consensus algorithm BMI is only a screening input — the diagnosis rests on the muscle-function test and the body composition measurement, which BMI cannot stand in for. UK guidance separately flags BMI's own blind spot, though it does not address sarcopenic obesity.

NICE advises clinicians to "Interpret BMI with caution in adults with high muscle mass because it may be a less accurate measure of central adiposity in this group", and separately to interpret it with caution in people aged 65 and over, taking into account "the possible protective effect of having a slightly higher BMI when older". Its recommended adjunct, in adults with a BMI below 35 kg/m², is waist-to-height ratio, where 0.5 to 0.59 indicates increased central adiposity and 0.6 or more indicates further increased risk — the plain-English version being that people "should try and keep their waist to less than half their height". NICE, NG246

Note what waist-to-height ratio does and does not do. It reads where fat sits better than BMI, but says nothing about how much muscle you have or how strong it is — the gap the function test and body composition scan exist to fill.

Why does sarcopenic obesity matter more than obesity alone?

In a large British cohort of older men, those with both problems had the highest all-cause mortality risk of the four groups compared — though the finding does not extend to every cardiovascular outcome.

The British Regional Heart Study followed 4,111 men aged 60 to 79 for a mean of 11.3 years. Using waist circumference and midarm muscle circumference as pre-consensus markers, 195 men (4.7%) were classed as sarcopenic obese. For all-cause mortality, risk was "significantly greater in sarcopenic (HR = 1.41, 95% CI = 1.22–1.63) and obese (HR = 1.21, 95% CI = 1.03–1.42) men than in the optimal reference group, with the highest risk in sarcopenic obese (HR = 1.72, 95% CI = 1.35–2.18), after adjustment for lifestyle characteristics". Atkins et al., Journal of the American Geriatrics Society, 2014

The caveat belongs in the same breath. In that study, "Risk of CVD mortality was significantly greater in sarcopenic and obese but not sarcopenic obese men", and no association was seen with coronary or cardiovascular events. Atkins et al., Journal of the American Geriatrics Society, 2014 The signal is on all-cause mortality, in older men, on anthropometric rather than scan-based criteria — not a blanket claim about every endpoint.

There is a skeletal dimension too: low muscle and low bone density frequently occur together, a combination covered in our guide to osteosarcopenia.

What can you do about sarcopenic obesity?

Train for strength, eat enough protein, and stop treating the scales as the scoreboard.

The aim is two-directional: reduce fat while preserving or increasing muscle mass and function. On exercise, the clinical overview reports that "Combining both resistance and aerobic exercise is more effective in improving skeletal muscle mass and function, and concurrently promoting adipose tissue loss (total, relative and trunk) in individuals with sarcopenic obesity, than either form of exercise alone". Citing the American College of Sports Medicine, it describes strength training on "a minimum of two non-consecutive days each week", with 8 to 12 repetitions for healthy adults or 10 to 15 for older and frailer people. On nutrition it sets out "Protein intake of 1.0–1.2 g/kg body weight" as strongly recommended for maintaining and recovering muscle over the long term, with a higher 1.2–1.5 g/kg proposed where multiple conditions are present, and roughly 25 to 30 g per meal in practice. Prado et al., Nature Reviews Endocrinology, 2024

None of that is exotic, which is rather the point: resistance training loads muscle and bone in the same session, and needs no diagnosis first.